JP2024506116A - アミノヘテロアリールキナーゼ阻害剤 - Google Patents
アミノヘテロアリールキナーゼ阻害剤 Download PDFInfo
- Publication number
- JP2024506116A JP2024506116A JP2023531615A JP2023531615A JP2024506116A JP 2024506116 A JP2024506116 A JP 2024506116A JP 2023531615 A JP2023531615 A JP 2023531615A JP 2023531615 A JP2023531615 A JP 2023531615A JP 2024506116 A JP2024506116 A JP 2024506116A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- independently selected
- pharmaceutically acceptable
- acceptable salt
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D309/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Control Of El Displays (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2020/132454 | 2020-11-27 | ||
| CN2020132454 | 2020-11-27 | ||
| CNPCT/CN2021/081236 | 2021-03-17 | ||
| CN2021081236 | 2021-03-17 | ||
| PCT/CN2021/133429 WO2022111621A1 (en) | 2020-11-27 | 2021-11-26 | Aminoheteroaryl kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024506116A true JP2024506116A (ja) | 2024-02-09 |
| JP2024506116A5 JP2024506116A5 (https=) | 2024-12-04 |
| JPWO2022111621A5 JPWO2022111621A5 (https=) | 2024-12-04 |
Family
ID=81753779
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531615A Pending JP2024506116A (ja) | 2020-11-27 | 2021-11-26 | アミノヘテロアリールキナーゼ阻害剤 |
| JP2024531423A Pending JP2024541533A (ja) | 2020-11-27 | 2022-11-23 | アミノヘテロアリールキナーゼ阻害薬 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531423A Pending JP2024541533A (ja) | 2020-11-27 | 2022-11-23 | アミノヘテロアリールキナーゼ阻害薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240166635A1 (https=) |
| EP (2) | EP4251613A4 (https=) |
| JP (2) | JP2024506116A (https=) |
| KR (1) | KR20230127228A (https=) |
| CN (2) | CN116528869B (https=) |
| AU (3) | AU2021385745C1 (https=) |
| CA (2) | CA3202990A1 (https=) |
| IL (1) | IL303237A (https=) |
| MX (1) | MX2024006300A (https=) |
| WO (2) | WO2022111621A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230127228A (ko) * | 2020-11-27 | 2023-08-31 | 올오리온 테라퓨틱스 인크. | 아미노헤테로아릴 키나아제 억제제 |
| CA3207392A1 (en) * | 2021-02-05 | 2022-08-11 | Xiaoxia Yan | Cdk inhibitor |
| EP4532473A1 (en) * | 2022-05-27 | 2025-04-09 | Allorion Therapeutics Inc. | Aminoheteroaryl kinase inhibitors |
| EP4731620A1 (en) * | 2023-06-25 | 2026-04-29 | Allorion Therapeutics Inc | Isotopologues of aminoheteroaryl kinase inhibitors and uses thereof |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
| EP4725942A1 (en) * | 2024-10-09 | 2026-04-15 | Sibylla Biotech S.p.A. | Compounds active on cyclin d1 pathway and their use |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004533458A (ja) * | 2001-05-30 | 2004-11-04 | アストラゼネカ アクチボラグ | サイクリン依存性キナーゼ阻害剤としての２−アニリノ−ピリミジン誘導体 |
| JP2004535414A (ja) * | 2001-05-29 | 2004-11-25 | シエーリング アクチエンゲゼルシャフト | Ｃｄｋ阻害性ピリミジン、それらの製造および薬剤としての使用 |
| WO2005009443A1 (en) * | 2003-06-24 | 2005-02-03 | Amgen Inc. | 2-amino-4-hydroxy-5-pyrimidinecarboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases |
| JP2005526765A (ja) * | 2002-03-11 | 2005-09-08 | シエーリング アクチエンゲゼルシャフト | Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用 |
| WO2008079291A2 (en) * | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| JP2010524952A (ja) * | 2007-04-16 | 2010-07-22 | ハッチソン メディファーマ エンタープライジズ リミテッド | ピリミジン誘導体 |
| CN110386901A (zh) * | 2018-04-23 | 2019-10-29 | 上海医药工业研究院 | 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用 |
| WO2019213340A1 (en) * | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
| JP2023547678A (ja) * | 2020-11-04 | 2023-11-13 | ユミコア | 充電式電池用正極活物質 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004888D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| GB0016877D0 (en) * | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
| GB0021726D0 (en) * | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| EP1343782B1 (en) * | 2000-12-21 | 2009-05-06 | SmithKline Beecham Corporation | Pyrimidineamines as angiogenesis modulators |
| KR20040062557A (ko) * | 2001-11-01 | 2004-07-07 | 얀센 파마슈티카 엔.브이. | 글리코겐 신타제 키나제 3β 억제제로서의아미노벤즈아미드 유도체 |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| BR0316680A (pt) * | 2002-11-28 | 2005-10-18 | Schering Ag | Pirimidinas inibidoras de chk, pdk e akt, sua produção e uso como agentes farmacêuticos |
| DE102005008310A1 (de) * | 2005-02-17 | 2006-08-24 | Schering Ag | Verwendung von CDKII Inhibitoren zur Fertilitätskontrolle |
| WO2006122003A2 (en) * | 2005-05-05 | 2006-11-16 | Ardea Biosciences, Inc. | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
| RU2009140319A (ru) * | 2007-04-02 | 2011-05-10 | Палау Фарма С.А. (Es) | Производные пирролпиримидина |
| BRPI0810411B8 (pt) * | 2007-04-18 | 2021-05-25 | Pfizer Prod Inc | derivados de sulfonil amida para o tratamento de crescimento celular anormal, seu sos, bem como composição farmacêutica |
| EP2179992A1 (de) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| AR074209A1 (es) * | 2008-11-24 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de pirimidina utiles para el tratamiento del cancer |
| DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
| CN103958482B (zh) * | 2011-11-29 | 2017-06-09 | 健泰科生物技术公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
| NZ629830A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| WO2020205560A1 (en) * | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| JP2023515629A (ja) * | 2020-02-28 | 2023-04-13 | フォチョン・バイオサイエンシーズ・リミテッド | Ｃｄｋ２／４／６阻害剤としての化合物 |
| KR20230127228A (ko) * | 2020-11-27 | 2023-08-31 | 올오리온 테라퓨틱스 인크. | 아미노헤테로아릴 키나아제 억제제 |
| CA3207392A1 (en) * | 2021-02-05 | 2022-08-11 | Xiaoxia Yan | Cdk inhibitor |
-
2021
- 2021-11-26 KR KR1020237021724A patent/KR20230127228A/ko active Pending
- 2021-11-26 EP EP21897121.6A patent/EP4251613A4/en active Pending
- 2021-11-26 CN CN202180079929.6A patent/CN116528869B/zh active Active
- 2021-11-26 AU AU2021385745A patent/AU2021385745C1/en active Active
- 2021-11-26 JP JP2023531615A patent/JP2024506116A/ja active Pending
- 2021-11-26 IL IL303237A patent/IL303237A/en unknown
- 2021-11-26 US US18/254,573 patent/US20240166635A1/en active Pending
- 2021-11-26 CA CA3202990A patent/CA3202990A1/en active Pending
- 2021-11-26 WO PCT/CN2021/133429 patent/WO2022111621A1/en not_active Ceased
-
2022
- 2022-11-23 AU AU2022397678A patent/AU2022397678A1/en active Pending
- 2022-11-23 WO PCT/CN2022/133770 patent/WO2023093769A1/en not_active Ceased
- 2022-11-23 JP JP2024531423A patent/JP2024541533A/ja active Pending
- 2022-11-23 MX MX2024006300A patent/MX2024006300A/es unknown
- 2022-11-23 EP EP22897852.4A patent/EP4436959A4/en active Pending
- 2022-11-23 CN CN202280077473.4A patent/CN118475562A/zh active Pending
- 2022-11-23 CA CA3238970A patent/CA3238970A1/en active Pending
-
2024
- 2024-05-21 US US18/670,469 patent/US20250002480A1/en active Pending
-
2025
- 2025-01-02 AU AU2025200001A patent/AU2025200001A1/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004535414A (ja) * | 2001-05-29 | 2004-11-25 | シエーリング アクチエンゲゼルシャフト | Ｃｄｋ阻害性ピリミジン、それらの製造および薬剤としての使用 |
| JP2004533458A (ja) * | 2001-05-30 | 2004-11-04 | アストラゼネカ アクチボラグ | サイクリン依存性キナーゼ阻害剤としての２−アニリノ−ピリミジン誘導体 |
| JP2005526765A (ja) * | 2002-03-11 | 2005-09-08 | シエーリング アクチエンゲゼルシャフト | Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用 |
| WO2005009443A1 (en) * | 2003-06-24 | 2005-02-03 | Amgen Inc. | 2-amino-4-hydroxy-5-pyrimidinecarboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases |
| WO2008079291A2 (en) * | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| JP2010524952A (ja) * | 2007-04-16 | 2010-07-22 | ハッチソン メディファーマ エンタープライジズ リミテッド | ピリミジン誘導体 |
| WO2009022171A1 (en) * | 2007-08-13 | 2009-02-19 | Astrazeneca Ab | Pyridinyiioxy pyridines as alk5 inhibitors |
| CN110386901A (zh) * | 2018-04-23 | 2019-10-29 | 上海医药工业研究院 | 含磺酰苯胺嘧啶结构的化合物及其作为抗肿瘤药物的应用 |
| WO2019213340A1 (en) * | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
| JP2023547678A (ja) * | 2020-11-04 | 2023-11-13 | ユミコア | 充電式電池用正極活物質 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4436959A4 (en) | 2026-02-11 |
| CA3202990A1 (en) | 2022-06-02 |
| US20250002480A1 (en) | 2025-01-02 |
| WO2023093769A1 (en) | 2023-06-01 |
| KR20230127228A (ko) | 2023-08-31 |
| AU2025200001A1 (en) | 2025-01-23 |
| CN118475562A (zh) | 2024-08-09 |
| AU2021385745B2 (en) | 2024-10-03 |
| CA3238970A1 (en) | 2023-06-01 |
| JP2024541533A (ja) | 2024-11-08 |
| AU2022397678A1 (en) | 2024-05-30 |
| EP4436959A1 (en) | 2024-10-02 |
| US20240166635A1 (en) | 2024-05-23 |
| EP4251613A1 (en) | 2023-10-04 |
| AU2021385745C1 (en) | 2025-02-20 |
| IL303237A (en) | 2023-07-01 |
| CN116528869B (zh) | 2026-04-14 |
| WO2022111621A1 (en) | 2022-06-02 |
| CN116528869A (zh) | 2023-08-01 |
| MX2024006300A (es) | 2024-07-24 |
| AU2021385745A9 (en) | 2025-03-27 |
| AU2021385745A1 (en) | 2023-06-15 |
| EP4251613A4 (en) | 2024-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI894229B (zh) | 作為yap/taz-tead蛋白-蛋白相互作用抑制劑之聯芳基衍生物 | |
| JP2024506116A (ja) | アミノヘテロアリールキナーゼ阻害剤 | |
| JP7641957B2 (ja) | Ｐａｒｐ７阻害剤としてのピリダジノン | |
| KR102757890B1 (ko) | 화합물, 조성물 및 방법 | |
| US20250154148A1 (en) | Kras inhibitors | |
| JP5814467B2 (ja) | キナーゼ阻害剤としてのイミダゾ［１，２−ｂ］ピリダジン誘導体 | |
| CA2935071A1 (en) | Piperidine-dione derivatives | |
| CN113993859B (zh) | 杂环化合物、其制备方法及其使用方法 | |
| CA2770475A1 (en) | Novel pyrrolidine derived beta 3 adrenergic receptor agonists | |
| AU2018337138B2 (en) | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof | |
| US20250320185A1 (en) | Aminoheteroaryl kinase inhibitors | |
| JP2016514709A (ja) | ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン | |
| EP4562016A2 (en) | Cdk2 inhibitors and methods of using the same | |
| CA2631661A1 (en) | Nitroimidazole compounds | |
| KR20240021923A (ko) | Parp7 억제제 및 이의 용도 | |
| HK40092567A (zh) | 氨基杂芳基激酶抑制剂 | |
| CN112876419A (zh) | 烯丙胺衍生物及其制备方法和用途 | |
| JP2006527266A (ja) | Ｃ型肝炎ウイルスの抑制剤 | |
| EA047452B1 (ru) | Биарильные производные в качестве ингибиторов белок-белкового взаимодействия yap/taz-tead | |
| OA20759A (en) | Benzimidazole derivatives. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20231124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231128 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20240819 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240820 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240823 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241126 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241126 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250925 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251007 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20251017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260406 |